This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Jung Lee, Ph.D.
Vice President of Business Development at Harbour Antibodies US, Inc.


Jung Lee is currently VP of Business Development at Harbour BioMed.  Before joining Harbour BioMed, he consulted few companies including a gene therapy company, negotiating and closing a joint venture in Spain and few license agreements.  Prior to consulting, Jung Lee was Head of Technology Partnering and Strategy at AstraZeneca (MedImmune), where he was responsible for overseeing all business development transactions for technologies that would benefit research and development of any biologic drugs. 

Prior to his tenure at AstraZeneca, Jung Lee was Executive Director at Martek Biosciences Corporation (acquired by DSM in 2010); overseeing numerous activities such as business development, innovation, and sales & marketing in Japan and Korea   Jung Lee also managed the Martek’s fluorescence pigment business unit until the fluorescence business was spun out. 

Before he started his business development career, he held key research positions and led numerous research programs in both GSK and Johnson & Johnson.  He has published thirteen research articles in internally recognized journals, mostly as a first author, and written a review chapter.  He was an inventor to twenty granted patents and patent applications.  Jung Lee obtained his Ph.D. degree from the University of Michigan and was a postdoctoral fellow at MIT.

Agenda Sessions

  • The Latest progress of the Harbour Mice® Platform